NASDAQ: CTMX - CytomX Therapeutics, Inc.

Yield per half year: -35.41%
Dividend yield: 0.00%
Sector: Healthcare

Share chart CytomX Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. работает как биофармацевтическая компания, специализирующаяся на онкологии, в США. Компания разрабатывает новый класс исследуемых терапевтических средств на основе антител на основе своей технологической платформы Probody для лечения рака.

more details
Его продукты-кандидаты на клинической стадии включают CX-072, иммуноонкологическую мишень лиганда 1 запрограммированной гибели клеток с терапевтическим нацеливанием на антитела; CX-2009, конъюгат "антитело-лекарственное средство" (PDC) против нового лекарственного средства-мишени CD166; BMS-986249, терапевтический препарат CTLA-4 Probody для лечения метастатической меланомы; CX-2029, PDC, нацеленный на CD71 для солидных опухолей; и BMS-986288, лекарственное средство против антитела CTLA-4 для солидных опухолей. Компания имеет стратегическое сотрудничество с AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc. и Astellas Pharma Inc. для разработки терапевтических препаратов Probody. CytomX Therapeutics, Inc. была основана в 2008 году, ее штаб-квартира находится в Южном Сан-Франциско, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2015-10-08
ISIN US23284F1057
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://www.cytomx.com
Цена ао 0.7945
Change price per day: 0% (0.7945)
Change price per week: -8.68% (0.87)
Change price per month: -5.53% (0.841)
Change price per 3 month: -20.55% (1)
Change price per half year: -35.41% (1.23)
Change price per year: -47.03% (1.5)
Change price per 3 year: -80.29% (4.03)
Change price per 5 year: -88.12% (6.69)
Change price per 10 year: 0% (0.7945)
Change price per year to date: -27.11% (1.09)
All parameters

Underestimation

Title Value Grade
P/S 1.05 9
P/BV -2.24 0
P/E 0 0
EV/EBITDA -23.92 0
Total: 4.88

Efficiency

Title Value Grade
ROA, % -0.2774 0
ROE, % 1.2 1
Total: 0.8333

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -3.24 10
Total: 9

Growth impulse

Title Value Grade
Yield Revenue, % 76.02 8
Yield Ebitda, % -96.11 0
Yield EPS, % -99.66 0
Total: 1.6
More

Institutions Volume Share, %
BVF Inc. 6595801 9.74
Tang Capital Management, LLC 6550000 9.67
Vanguard Group Inc 4902943 7.24
Acadian Asset Management. LLC 2646190 3.91
Renaissance Technologies, LLC 1325700 1.96
Blackrock Inc. 1136135 1.68
Laurion Capital Management, LP 1093921 1.62
Bronte Capital Management Pty Ltd. 919911 1.36
Millennium Management LLC 794047 1.17
Jacobs Levy Equity Management, Inc. 791421 1.17

ETF Share, % Profitability for 1 year, % Dividends, %
Formidable ETF 1.27439 9.18 4.44452
iShares Micro-Cap ETF 0.02347 17.09 1.54048



Head Job title Payment Year of birth
Mr. Lloyd A. Rowland Jr., J.D. Senior VP, General Counsel, Chief Compliance Officer & Secretary 608.72k 1957 (68 years)
Mr. Christopher W. Ogden Chief Financial Officer N/A 1984 (41 year)
Ms. Leslie Robbins Senior Vice President of Intellectual Property N/A
Dr. Marcia P. Belvin Ph.D. Senior VP & Chief Scientific Officer N/A
Mr. Jeffrey Landau B.S., M.B.A. Senior VP, Head of Strategy & Chief Business Officer 581.68k 1979 (46 years)
Ms. Danielle Olander-Moghadassian Senior VP & Chief Human Resources Officer N/A
Dr. Yu-Waye Chu M.D. Chief Medical Officer N/A 1968 (57 years)
Ms. Dawn Benson Senior Vice President of Quality & Product Manufacturing N/A
Dr. Sean A. McCarthy DPHIL Chairman & CEO 1.03M 1967 (58 years)
Dr. Hoyoung Huh M.D., Ph.D. Special Advisor to Chief Executive Officer 1969 (56 years)

Address: United States, South San Francisco, CA , 151 Oyster Point Boulevard - open in Google maps, open in Yandex maps
Website: https://www.cytomx.com